Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
Sep 11

DJ Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses On The Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Edwards Lifesciences Corp. $(EW)$ shed 1.90% to $78.28 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.30% to 6,532.04 and the Dow Jones Industrial Average falling 0.48% to 45,490.92.

This was the stock's sixth consecutive day of losses.

Edwards Lifesciences Corp. closed 5.69% short of its 52-week high of $83.00, which the company achieved on July 25th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Abbott Laboratories $(ABT)$ fell 1.96% to $129.36, Medtronic PLC $(MDT)$ fell 1.86% to $92.32, and Stryker Corp. $(SYK)$ fell 2.49% to $382.97.

Trading volume (3.9 M) remained 214,113 below its 50-day average volume of 4.1 M.

Data source: Dow Jones Market Data, FactSet. Data compiled September 10, 2025.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

September 10, 2025 16:50 ET (20:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10